Table 3 Comparison of patient in Derivation and Validation phase
Total, No. (%) | Derivation | Validation | ||||
|---|---|---|---|---|---|---|
Cases (ESBL-PE) n = 265 (37) | Controls (non-ESBL-PE) n = 445 (63) | p | ESBL-PE n = 188 (19) | non-ESBL-PE n = 797 (81) | p | |
Age, median (IQR), years | 56 (39–67) | 60 (47–70) | 0.009 | 55 (38–67) | 59 (45–70) | 0.009 |
Men | 148 (56) | 286 (64) | 0.026 | 80 (43) | 309 (39) | 0.340 |
Emergency room at index culture | 231 (87) | 425 (96) | 0.000 | 93 (59) | 405 (51) | 0.850 |
Prolonged hospitalization (≥7 days) | 119 (45) | 141 (32) | 0.000 | 72 (38) | 244 (30) | 0.042 |
Hospitalization during previous year | 223 (84) | 264 (59) | 0,000 | 129 (69) | 542 (68) | 0.871 |
Immunosuppressive therapya | 27 (10) | 19 (4) | 0.002 | 4 (2) | 10 (1) | 0.363 |
Chemotherapya | 89 (34) | 183 (41) | 0.046 | 79 (42) | 330 (41) | 0.877 |
Invasive device at the time of cultureb | 146 (55) | 177 (40) | 0.000 | 98 (52) | 348 (43) | 0.036 |
Neoplasia in remission | 20 (8) | 17 (4) | 0.031 | 11 (6) | 30 (4) | 0.197 |
Neutropenia | 59 (22) | 68 (15) | 0.019 | 28 (15) | 97 (12) | 0.313 |
Beta-lactam use | 80 (31) | 82 (18) | 0,000 | 49 (26) | 99 (12) | 0.000 |
Isolate source | ||||||
Blood | 63 (23) | 86 (19) | 0.384 | 30 (16) | 154 (19) | 0.651 |
Urinary tract | 142 (54) | 272 (61) | 123 (65) | 485 (61) | ||
Surgical wound | 47 (18) | 68 (15) | 11 (6) | 62 (8) | ||
Skin and soft tissues | 3 (1) | 4 (1) | 17 (9) | 62 (8) | ||
Lower respiratory tract | 10 (4) | 15 (3) | 7 (4) | 34 (4) | ||
Isolated microorganism | ||||||
E. coli. | 166 (63) | 299 (67) | 0.000 | 134 (71) | 505 (63) | 0.002 |
Klebsiella spp. | 92 (35) | 80 (18) | 33 (18) | 148 (19) | ||
Proteus spp. | 3 (1) | 55 (12) | 5 (3) | 94 (12) | ||
Others | 4 (2) | 11 (2) | 16 (9) | 50 (6) | ||